Here’s the content from the provided sources, formatted for easy reading:
New blood test uses cell-free DNA shed from placenta to accurately predict preterm preeclampsia
A new blood test has an 80% accuracy in predicting preterm preeclampsia, according to a study published today, Feb. 12, in the journal Nature medicine. The condition, which results in over 70,000 maternal deaths and 500,000 fetal deaths each year worldwide, has long been hard to predict. This makes proactive treatment challenging, according to one of the study’s lead authors.
The test uses cell-free DNA shed from the placenta, which can be detected in the bloodstream. Researchers developed and validated the test using samples from over 1,000 pregnant individuals between 2017-2023. The approach uses signals stored within circulating cell-free DNA sequence data and had 80% sensitivity in predicting preterm preeclampsia.
Funding for the study came from the National Institutes of Health (K23 CA237746,DP2 186 CA280624,K08 HL150169,R21 HD086620,and UL1 TR002319).
New blood test could make preeclampsia easier to predict,early study suggests
A blood test given as early as the end of the frist trimester of pregnancy could help identify patients at the highest risk of preeclampsia,a possibly life-threatening condition associated with high blood pressure during pregnancy. The test uses cell-free DNA shed from the placenta and has shown an 80% accuracy rate in predicting preterm preeclampsia.
Researchers hope that with further progress and larger trials, this test could become an early preeclampsia prediction tool that seamlessly integrates into routine early pregnancy screening. The study was funded by the National Institutes of Health.
New blood test accurately predicts preeclampsia
A new blood test has an 80% accuracy in predicting preterm preeclampsia, according to a study published in Nature Medicine. The test uses cell-free DNA from the placenta and was developed and validated using samples from over 1,000 pregnant individuals.
Researchers plan to improve the test’s training model with more samples and ultimately conduct a trial with thousands of patients. Thay believe the test could become an early preeclampsia prediction tool that integrates into routine early pregnancy screening. The study was funded by the National Institutes of Health.
New Blood Test Accurately Predicts preeclampsia
Table of Contents
- New Blood Test Accurately Predicts preeclampsia
- Editor’s Interview with Lead Researcher
- Q: Can you explain how this new blood test works?
- Q: What makes this test meaningful in the context of preeclampsia screening?
- Q: What is the accuracy rate of this test, and how was it persistent?
- Q: What are the next steps for this research?
- Q: How does this test fit into the current landscape of preeclampsia management?
- Q: How was this research funded?
- Conclusion
- Editor’s Interview with Lead Researcher
A new blood test has an 80% accuracy in predicting preterm preeclampsia, according to a study published in Nature Medicine. The test uses cell-free DNA from the placenta and was developed and validated using samples from over 1,000 pregnant individuals.
Editor’s Interview with Lead Researcher
Q: Can you explain how this new blood test works?
Researcher: The test detects cell-free DNA shed from the placenta. By analyzing this DNA, we can identify markers that indicate an increased risk of preeclampsia, a potentially life-threatening condition characterized by high blood pressure during pregnancy.
Q: What makes this test meaningful in the context of preeclampsia screening?
Researcher: Current screening methods for preeclampsia are limited and frequently enough rely on clinical risk factors that may not be present until later in pregnancy. Our test, which can be administered as early as the end of the first trimester, offers a more proactive approach to identifying patients at the highest risk.This early detection can significantly improve maternal and fetal outcomes.
Q: What is the accuracy rate of this test, and how was it persistent?
Researcher: The test has shown an 80% accuracy rate in predicting preterm preeclampsia. This was determined through extensive validation using samples from over 1,000 pregnant individuals. Our goal is to continue improving the training model with more samples to enhance accuracy even further.
Q: What are the next steps for this research?
Researcher: We plan to conduct larger trials with thousands of patients. our ultimate aim is to integrate this test into routine early pregnancy screening. With further progress and larger trials, we hope to make this an essential tool for obstetricians and midwives to better manage pregnancies at risk of preeclampsia.
Q: How does this test fit into the current landscape of preeclampsia management?
Researcher: Current management strategies often involve frequent monitoring and intervention later in pregnancy. Our test provides an early warning system that can lead to more personalized and proactive care plans. This could include lifestyle modifications, closer monitoring, and timely intervention to prevent severe complications.
Q: How was this research funded?
Researcher: The study was funded by the National Institutes of Health. Their support has been crucial in advancing our research and bringing us closer to a practical and effective tool for early preeclampsia prediction.
Conclusion
This innovative blood test, utilizing cell-free DNA from the placenta, holds great promise for early prediction of preeclampsia. With an 80% accuracy rate and potential for integration into routine early pregnancy screening, it could revolutionize the management of pregnancies at risk. Future trials and enhancements aim to further refine this tool, making it a vital asset in obstetric care.
